GENFIT (GNFT)
(Delayed Data from NSDQ)
$3.93 USD
-0.18 (-4.38%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $3.92 -0.01 (-0.25%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Brokerage Reports
GENFIT S.A. Unsponsored ADR [GNFT]
Reports for Purchase
Showing records 81 - 100 ( 117 total )
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
NIS4 Leads the Way for Non-Invasive NASH Dx in T2DM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Healthcare - Earnings Recap: Halftime Show of Our Most In-Depth, Differentiated Earnings Yet
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Healthcare - Accelerating the Pace: Perspectives From Our 3rd Annual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
3Q19 - Anticipation for 1Q20 RESOLVE-IT Readout Reaching a Peak
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Despite Skeptics, We Continue to See Positive Phase 3 NASH Data in 1Q20; Reduce PT to $58
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Healthcare - Should You Attend AASLD in Boston? Use Our Day-By-Day Calendar to Figure It Out
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Final Program for Our Third Annual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Program for Our Third Annual NASH Investor Conference, October 21, New York
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Healthcare - The Liver Meeting Abstracts Part 2: Our Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
1H19 Recap - Shares at Compelling Entry Point, Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
After Two Decades, CEO Mouney Passes the Baton, But Remains Chairman; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
What Does It Take to Lift the Low NASH Sentiment?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Takeaways from Our Doc Call with Dr. Vlad Ratziu
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Elafibranor Granted Orphan Drug Designation in PBC; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.